Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).

MLA

L Perey, et al. “Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and Primary or Acquired Resistance to Aromatase Inhibitors: Final Results of Phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).” Annals of Oncology, vol. 18, no. 1, Jan. 2007, pp. 64–69. EBSCOhost, https://doi.org/10.1093/annonc/mdl341.

APA

L Perey, R Paridaens, H Hawle, K Zaman, F Nolé, H Wildiers, M Fiche, D Dietrich, P Clément, D Köberle, A Goldhirsch, & B Thürlimann. (2007). Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Annals of Oncology, 18(1), 64–69. https://doi.org/10.1093/annonc/mdl341

Chicago

L Perey, R Paridaens, H Hawle, K Zaman, F Nolé, H Wildiers, M Fiche, et al. 2007. “Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and Primary or Acquired Resistance to Aromatase Inhibitors: Final Results of Phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00).” Annals of Oncology 18 (1): 64–69. doi:10.1093/annonc/mdl341.